Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
20 Febbraio 2025 - 10:05PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2025
Commission file number: 001-40231
Universe Pharmaceuticals INC
265 Jingjiu Avenue
Jinggangshan Economic and Technological Development
Zone
Ji’an, Jiangxi, China 343100
+86-0796-8403309
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒
Form 40-F ☐
Result of the February 2025 Extraordinary General Meeting of Shareholders
On February 19, 2025, Universe Pharmaceuticals
INC (the “Company”) re-convened its extraordinary general meeting of shareholders, originally convened on February 17, 2025
(the “February 2025 Extraordinary General Meeting”) at 10:00 a.m., Beijing Time, at 265 Jingjiu Avenue, Jinggangshan Economy
and Technology Development Zone, Ji’an City, Jiangxi 343100, the People’s Republic of China.
At the February 2025 Extraordinary General Meeting,
shareholders of the Company passed an ordinary resolution approving the indefinite adjournment of the February 2025 Extraordinary General
Meeting.
SIGNATURES
Pursuant to the requirements
of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
| |
Universe Pharmaceuticals INC. |
| |
|
| Date: February 20, 2025 |
By: |
/s/ Gang Lai |
| |
|
Gang Lai |
| |
|
Chief Executive Officer |
2
Grafico Azioni Universe Pharmaceuticals (NASDAQ:UPC)
Storico
Da Gen 2025 a Feb 2025
Grafico Azioni Universe Pharmaceuticals (NASDAQ:UPC)
Storico
Da Feb 2024 a Feb 2025
